Bordetella Bronchiseptica Vaccine
Nobivac Feline-Bb is an intranasal vaccine
containing an avirulent live culture of Bordetella bronchiseptica. Nobivac
Feline-Bb is presented in a desiccated form with sterile diluent provided for
Nobivac Feline-Bb is for vaccination of healthy kittens
and cats for prevention of disease caused by B. bronchiseptica.
Research has demonstrated that B.
bronchiseptica acts as a primary or secondary pathogen in feline respiratory
disease. Traditionally feline herpesvirus (FHV) and feline calicivirus (FCV)
have been implicated as the most common agents associated with feline upper
respiratory infection (URI). However studies have shown that B. bronchiseptica
may be the sole infectious agent in feline URI.(1) (2) Clinical signs associated
with B. bronchiseptica infection may include fever sneezing nasal discharge
coughing and submandibular lymphadenopathy. In some cases the infection
progresses to pneumonia. Research regarding interspecies transmission has
demonstrated isolates from cats and dogs housed in the same location were
similar if not identical.(3) Because B. bronchiseptica is transmitted by the
aerosol route animals in close confinement such as in catteries boarding
facilities hospitals or pet stores or cats from multi-cat households are at
greatest risk for infection.
Efficacy Data: Challenge studies have shown that kittens vaccinated at 4
weeks of age with Nobivac Feline-Bb were protected against disease when
challenged 3 weeks post-vaccination. Further studies to establish duration of
immunity have not yet been completed. Studies to evaluate the onset of immunity
have demonstrated protection against B. bronchiseptica 72 hours after
vaccination in 8 week old kittens.
Directions for Use: Aseptically reconstitute the
desiccated vaccine with the sterile diluent provided. Remove the needle and
administer 0.2 ml intranasally. Healthy kittens 8 weeks of age or older should
be vaccinated prior to confinement or when risk of exposure to B. bronchiseptica
1. Recommended storage temperature 35-45°F (2-7°C).
2. Shake well before use.
3. Use contents promptly once reconstituted.
4. Non-chemically sterilized syringes should be used for administration of
5. Administration of epinephrine may be indicated in the event of an
6. Burn this container and all unused contents.
7. Only healthy animals should be vaccinated. Animals incubating any disease or
animals stressed due to shipping malnutrition or parasitism may not achieve or
maintain an adequate immune response.
8. This product is not hazardous when used according to directions supplied.